Invasive growth associated with cold-inducible RNA-binding protein expression drives recurrence of surgically resected brain metastases.


Journal

Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420

Informations de publication

Date de publication:
01 09 2021
Historique:
pubmed: 13 1 2021
medline: 6 10 2021
entrez: 12 1 2021
Statut: ppublish

Résumé

Sixty percent of surgically resected brain metastases (BrM) recur within 1 year. These recurrences have long been thought to result from the dispersion of cancer cells during surgery. We tested the alternative hypothesis that invasion of cancer cells into the adjacent brain plays a significant role in local recurrence and shortened overall survival. We determined the invasion pattern of 164 surgically resected BrM and correlated with local recurrence and overall survival. We performed single-cell RNA sequencing (scRNAseq) of >15,000 cells from BrM and adjacent brain tissue. Validation of targets was performed with a novel cohort of BrM patient-derived xenografts (PDX) and patient tissues. We demonstrate that invasion of metastatic cancer cells into the adjacent brain is associated with local recurrence and shortened overall survival. scRNAseq of paired tumor and adjacent brain samples confirmed the existence of invasive cancer cells in the tumor-adjacent brain. Analysis of these cells identified cold-inducible RNA-binding protein (CIRBP) overexpression in invasive cancer cells compared to cancer cells located within the metastases. Applying PDX models that recapitulate the invasion pattern observed in patients, we show that CIRBP is overexpressed in highly invasive BrM and is required for efficient invasive growth in the brain. These data demonstrate peritumoral invasion as a driver of treatment failure in BrM that is functionally mediated by CIRBP. These findings improve our understanding of the biology underlying postoperative treatment failure and lay the groundwork for rational clinical trial development based upon invasion pattern in surgically resected BrM.

Sections du résumé

BACKGROUND
Sixty percent of surgically resected brain metastases (BrM) recur within 1 year. These recurrences have long been thought to result from the dispersion of cancer cells during surgery. We tested the alternative hypothesis that invasion of cancer cells into the adjacent brain plays a significant role in local recurrence and shortened overall survival.
METHODS
We determined the invasion pattern of 164 surgically resected BrM and correlated with local recurrence and overall survival. We performed single-cell RNA sequencing (scRNAseq) of >15,000 cells from BrM and adjacent brain tissue. Validation of targets was performed with a novel cohort of BrM patient-derived xenografts (PDX) and patient tissues.
RESULTS
We demonstrate that invasion of metastatic cancer cells into the adjacent brain is associated with local recurrence and shortened overall survival. scRNAseq of paired tumor and adjacent brain samples confirmed the existence of invasive cancer cells in the tumor-adjacent brain. Analysis of these cells identified cold-inducible RNA-binding protein (CIRBP) overexpression in invasive cancer cells compared to cancer cells located within the metastases. Applying PDX models that recapitulate the invasion pattern observed in patients, we show that CIRBP is overexpressed in highly invasive BrM and is required for efficient invasive growth in the brain.
CONCLUSIONS
These data demonstrate peritumoral invasion as a driver of treatment failure in BrM that is functionally mediated by CIRBP. These findings improve our understanding of the biology underlying postoperative treatment failure and lay the groundwork for rational clinical trial development based upon invasion pattern in surgically resected BrM.

Identifiants

pubmed: 33433612
pii: 6089125
doi: 10.1093/neuonc/noab002
pmc: PMC8408858
doi:

Substances chimiques

RNA-Binding Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1470-1480

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Matthew Dankner (M)

Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada.
Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada.
McGill Faculty of Medicine, McGill University, Montreal, Quebec, Canada.

Maxime Caron (M)

McGill University Genome Centre, Department of Human Genetics, McGill University, Montreal, Quebec, Canada.

Tariq Al-Saadi (T)

McGill Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.

WenQing Yu (W)

McGill Faculty of Medicine, McGill University, Montreal, Quebec, Canada.

Véronique Ouellet (V)

Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.

Rima Ezzeddine (R)

Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada.
Department of Biochemistry, McGill University, Montreal, Quebec, Canada.

Sarah M Maritan (SM)

Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada.
Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada.
McGill Faculty of Medicine, McGill University, Montreal, Quebec, Canada.

Matthew G Annis (MG)

Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada.

Phuong Uyen Le (PU)

McGill Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.

Javad Nadaf (J)

McGill University Genome Centre, Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.

Noah S Neubarth (NS)

Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada.
Department of Anatomy and Cell Biology, McGill University, Montreal, Quebec, Canada.

Paul Savage (P)

Department of Surgery, University of Toronto, Toronto, Ontario, Canada.

Dongmei Zuo (D)

Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada.

Charles P Couturier (CP)

McGill Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.

Jean Monlong (J)

McGill University Genome Centre, Department of Human Genetics, McGill University, Montreal, Quebec, Canada.

Haig Djambazian (H)

McGill University Genome Centre, Department of Human Genetics, McGill University, Montreal, Quebec, Canada.

Huda Altoukhi (H)

McGill Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
Department of Radiation Oncology, McGill University, Montreal, Quebec, Canada.

Guillaume Bourque (G)

McGill University Genome Centre, Department of Human Genetics, McGill University, Montreal, Quebec, Canada.

Jiannis Ragoussis (J)

McGill University Genome Centre, Department of Human Genetics, McGill University, Montreal, Quebec, Canada.

Roberto J Diaz (RJ)

McGill Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.

Morag Park (M)

Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada.
Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada.
McGill Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
Department of Biochemistry, McGill University, Montreal, Quebec, Canada.
Department of Pathology, McGill University, Montreal, Quebec, Canada.

Marie-Christine Guiot (MC)

Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada.
McGill Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.
Department of Pathology, McGill University, Montreal, Quebec, Canada.

Stephanie Lam (S)

McGill Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
Department of Diagnostic Radiology, McGill University, Montreal, Quebec, Canada.

Kevin Petrecca (K)

McGill Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, Montreal, Quebec, Canada.

Peter M Siegel (PM)

Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada.
Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada.
McGill Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
Department of Biochemistry, McGill University, Montreal, Quebec, Canada.
Department of Anatomy and Cell Biology, McGill University, Montreal, Quebec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH